Sirish Kishore1, Tamir Friedman1, David C Madoff2. 1. Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68th Street P-518, New York, NY, 10065, USA. 2. Department of Radiology, Division of Interventional Radiology, New York Presbyterian Hospital/Weill Cornell Medical Center, 525 East 68th Street P-518, New York, NY, 10065, USA. dcm9006@med.cornell.edu.
Abstract
PURPOSE OF REVIEW: The purpose of the review is to summarize the latest applications for embolotherapy in the management of patients with HCC according to BCLC stage. RECENT FINDINGS: While traditionally reserved for patients with unresectable HCC and stage B disease, there is an important role for embolization therapies in earlier stage patients as an adjunct to ablation, bridging, or downstaging therapy, as a means to improve safety of resection, and potentially as an arterial ablative option in the case of radioembolization. Newer applications of radioembolization such as radiation segmentectomy have the potential to provide cure in localized unifocal disease, and transarterial chemoembolization-portal vein embolization and radiation lobectomy may provide a combination of treatment and future liver remnant hypertrophy for planned hepatic resection. There is also an increasing role for embolization in the treatment of stage C disease, and recent data suggest it can be used in combination with sorafenib with the potential for survival benefit over sorafenib alone, even in the case of portal vein tumor thrombus. Embolization therapies play an increasingly important role in patients with BCLC stage A-C hepatocellular carcinoma. While different therapies may be offered on a patient-specific basis, there are limited prospective RCT data to support superiority of one technique over another.
PURPOSE OF REVIEW: The purpose of the review is to summarize the latest applications for embolotherapy in the management of patients with HCC according to BCLC stage. RECENT FINDINGS: While traditionally reserved for patients with unresectable HCC and stage B disease, there is an important role for embolization therapies in earlier stage patients as an adjunct to ablation, bridging, or downstaging therapy, as a means to improve safety of resection, and potentially as an arterial ablative option in the case of radioembolization. Newer applications of radioembolization such as radiation segmentectomy have the potential to provide cure in localized unifocal disease, and transarterial chemoembolization-portal vein embolization and radiation lobectomy may provide a combination of treatment and future liver remnant hypertrophy for planned hepatic resection. There is also an increasing role for embolization in the treatment of stage C disease, and recent data suggest it can be used in combination with sorafenib with the potential for survival benefit over sorafenib alone, even in the case of portal vein tumor thrombus. Embolization therapies play an increasingly important role in patients with BCLC stage A-C hepatocellular carcinoma. While different therapies may be offered on a patient-specific basis, there are limited prospective RCT data to support superiority of one technique over another.
Entities:
Keywords:
Bland embolization; Chemoembolization; Embolotherapy; Hepatocellular carcinoma; Locoregional therapy; Radioembolization
Authors: Y Sasaki; S Imaoka; H Kasugai; M Fujita; S Kawamoto; S Ishiguro; J Kojima; O Ishikawa; H Ohigashi; H Furukawa Journal: Cancer Date: 1987-09-15 Impact factor: 6.860
Authors: Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria Journal: Hepatology Date: 2011-06-30 Impact factor: 17.425
Authors: Daniel Seehofer; Maxim Nebrig; Timm Denecke; Thomas Kroencke; Wilko Weichert; Martin Stockmann; Rajan Somasundaram; Eckart Schott; Gero Puhl; Peter Neuhaus Journal: Clin Transplant Date: 2012-03-20 Impact factor: 2.863
Authors: Ahsun Riaz; Vanessa L Gates; Bassel Atassi; Robert J Lewandowski; Mary F Mulcahy; Robert K Ryu; Kent T Sato; Talia Baker; Laura Kulik; Ramona Gupta; Michael Abecassis; Al B Benson; Reed Omary; Laura Millender; Andrew Kennedy; Riad Salem Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Samer Tohme; Daniel Sukato; Hui-Wei Chen; Nikhil Amesur; Albert B Zajko; Abhinav Humar; David A Geller; James W Marsh; Allan Tsung Journal: J Vasc Interv Radiol Date: 2013-11 Impact factor: 3.464
Authors: Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni Journal: Cardiovasc Intervent Radiol Date: 2009-11-12 Impact factor: 2.740
Authors: Matthew P Lungren; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh Thakor; Richard B Towbin; Anne Marie Cahill; C Matthew Hawkins Journal: Pediatr Radiol Date: 2018-01-23
Authors: Song Liu; Guangji Yu; Qingdong Wang; Long Li; Ying Liu; Ke Du; Fei Zhang; Bangli Zhao; Guangsheng Zhao Journal: Am J Transl Res Date: 2021-12-15 Impact factor: 4.060